Health and Healthcare
Safety Concern Offsets Chronic Kidney Disease Study Positive Results
Published:
On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). Shares were crushed afterward.
This is Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is seeking to treat anemia due to CKD in adult patients not on dialysis. Akebia’s vadadustat development program also includes two other global Phase 3 studies (INNO2VATE) for the treatment of anemia due to CKD in adult patients on dialysis, for which the company reported positive topline data in May.
Management noted that it believes the cardiovascular safety of vadadustat is supported by the totality of the data from the global Phase 3 program, including additional analyses on cardiovascular outcomes observed within key geographic regions and across certain patient sub-populations within the PRO2TECT study.
Vadadustat achieved each of the PRO2TECT studies’ primary efficacy endpoints as well as the key secondary efficacy endpoint. However, what ultimately crushed the stock was the fact that the study failed to meet the safety goal.
Again, management noted that while achieving the safety endpoint would have made the path more straightforward, as it is in dialysis, the firm still believes it has a path toward approval.
Looking ahead, Akebia is working to present the full dataset from its global Phase 3 program (INNO2VATE and PRO2TECT) at an upcoming medical conference and publish the data in peer-reviewed journals.
Also, Akebia plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to CKD in adult dialysis-dependent and non-dialysis dependent patients as early as possible in 2021.
Akebia stock traded down about 72% on Thursday to $2.77, in a 52-week range of $2.75 to $13.71. The consensus price target is $17.14.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
